Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
Valenza C, Trapani D, Zagami P, Antonarelli G, Boscolo Bielo L, Nicolò E, Ribeiro JM, Guidi L, Reduzzi C, Spotti M, Adamoli L, Cortès J, Pistilli B, Tolaney SM, Ueno N, Layman RM, Cristofanilli M, Carey LA, Munzone E, Criscitiello C, Lynce F, Woodward WA, Curigliano G. Valenza C, et al. Among authors: guidi l. Eur J Cancer. 2024 Dec;213:115097. doi: 10.1016/j.ejca.2024.115097. Epub 2024 Oct 28. Eur J Cancer. 2024. PMID: 39486164
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.
Cantini L, Trapani D, Guidi L, Boscolo Bielo L, Scafetta R, Koziej M, Vidal L, Saini KS, Curigliano G. Cantini L, et al. Among authors: guidi l. Cancer Treat Rev. 2024 Feb;123:102669. doi: 10.1016/j.ctrv.2023.102669. Epub 2023 Dec 10. Cancer Treat Rev. 2024. PMID: 38141462 Review.
Targeting HER2 heterogeneity in breast and gastrointestinal cancers.
Valenza C, Guidi L, Battaiotto E, Trapani D, Sartore Bianchi A, Siena S, Curigliano G. Valenza C, et al. Among authors: guidi l. Trends Cancer. 2024 Feb;10(2):113-123. doi: 10.1016/j.trecan.2023.11.001. Epub 2023 Nov 25. Trends Cancer. 2024. PMID: 38008666 Review.
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms.
Valenza C, Mongillo M, Gigli F, Trapani D, Katrini J, Nicolò E, Boldrini L, Boscolo Bielo L, Castellano G, Guidi L, Pellizzari G, Derio S, Lapresa M, Parma G, Derenzini E, Curigliano G, Colombo N. Valenza C, et al. Among authors: guidi l. ESMO Open. 2024 Sep;9(9):103685. doi: 10.1016/j.esmoop.2024.103685. Epub 2024 Aug 29. ESMO Open. 2024. PMID: 39214046 Free PMC article.
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study.
Guidi L, Valenza C, Battaiotto E, Trapani D, Ghioni MC, Crimini E, Boscolo Bielo L, Venetis K, Belli C, Bottiglieri L, Gervaso L, Cella CA, Ciardiello D, Spada F, Benini L, Adorisio R, Mane E, Fazio N, Guerini Rocco E, Curigliano G, Zampino MG. Guidi L, et al. ESMO Open. 2024 Aug;9(8):103662. doi: 10.1016/j.esmoop.2024.103662. Epub 2024 Aug 6. ESMO Open. 2024. PMID: 39111110 Free PMC article.
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.
Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, Curigliano G. Ascione L, et al. Among authors: guidi l. Am Soc Clin Oncol Educ Book. 2024 Jun 1;44(3):e431766. doi: 10.1200/EDBK_431766. Am Soc Clin Oncol Educ Book. 2024. PMID: 38828973 Free article. Review.
400 results